6505--Ranolazine Sustained Action (SA) Tablets
ID: 36E79725R0036Type: Presolicitation
AwardedJun 26, 2025
$11.7M$11,667,090
AwardeeRADHA PHARMACEUTICALS INC HAUPPAUGE 11788
Award #:36E79725D0043
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/228f8cc3026b4800b9e58fb98d9c1c75/view
Timeline
    Description

    The Department of Veterans Affairs is seeking proposals for the procurement of Ranolazine Sustained Action (SA) Tablets, a pharmaceutical product essential for veteran healthcare. Bidders are required to submit pricing for a base year and four option years, along with compliance with stringent packaging specifications and adherence to the Drug Supply Chain Security Act. This procurement underscores the government's commitment to ensuring a reliable supply of quality medications for veterans, reflecting regulatory compliance and fiscal responsibility. Interested parties should note that the deadline for receipt of offers has been extended to May 15, 2025, at 2:30 PM CT, and must acknowledge receipt of the amendment to be considered valid; for further inquiries, contact Nicholas I McGregor at Nicholas.McGregor@va.gov.

    Point(s) of Contact
    Deb FasslContract Specialist
    (708) 786-5894
    Deborah.Fassl@va.gov
    Files
    Title
    Posted
    36E79725R0036_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center is preparing to issue a Request for Proposal (RFP) for an unrestricted procurement of Ranolazine Sustained Action (SA) Tablets, applicable to various federal entities, including the VA, Department of Defense, and more. The RFP, numbered 36E79725R0036, will be publicly available on approximately April 21, 2025, with proposals due by May 6, 2025. The contract is expected to last one year, with four one-year extension options. Bidders must provide a unique National Drug Code (NDC) and ensure that their labeling adheres to specific packaging requirements, including a safety-cap standard. The estimated demand includes 229,028 bottles of 500 mg SA tablets and 95,925 bottles of 1000 mg SA tablets annually. All updates and amendments to the solicitation will be posted on SAM.gov, and interested parties should monitor this site for ongoing developments. Queries related to the RFP should be directed to Contract Specialist Deb Fassl via email.
    36E79725R0036.docx
    The document outlines a Request for Proposal (RFP) from the Department of Veterans Affairs for pharmaceutical products, specifically focusing on Ranolazine Sustained Action Tablets. It requires bidders to propose prices for both a base year and four option years, detailing quantities and compliance expectations. Key requirements include submission of National Drug Code (NDC) numbers, adherence to stringent packaging specifications, and compliance with the Drug Supply Chain Security Act. Contractors must maintain a business agreement with Pharmaceutical Prime Vendors (PPVs) and register products with the FDA within specified timeframes. Furthermore, the solicitation emphasizes the importance of contract execution by detailing the contract effective dates, implementation periods, and the procedures for addressing backorders. Bid submissions must include commitments from manufacturers or distributors, ensuring that proposed items meet federal standards, including Good Manufacturing Practices (cGMP). This request illustrates the federal commitment to providing consistent pharmaceutical supplies efficiently, reflecting regulatory compliance and fiscal responsibilities, while prioritizing veteran healthcare needs. Overall, it demonstrates the government’s systematic approach in securing necessary medical supplies, ensuring both quality and reliable access to essential medications.
    36E79725R0036 0001.docx
    The document is an amendment to solicitation number 36E79725R0036 issued by the Department of Veterans Affairs' OPAL/National Acquisition Center. The primary purpose of the amendment is to extend the deadline for receipt of offers from May 6, 2025, to May 13, 2025, at 2:30 PM CT. It emphasizes that all other terms and conditions of the solicitation remain unchanged. The amendment requires all offerors to acknowledge receipt of the amendment to ensure compliance with the extended deadline. This adjustment is significant as it allows potential bidders additional time to prepare their offers, aligning with the department's objective of encouraging participation in the bidding process while maintaining the integrity of the solicitation’s initial conditions. Overall, this amendment reflects standard procedural practices in government contracting, where adjustments to deadlines are made to enhance competition and ensure adequate preparation by bidders.
    36E79725R0036 0002.docx
    This document is an amendment to solicitation 36E79725R0036 issued by the Department of Veterans Affairs, specifically from the OPAL/National Acquisition Center in Hines, Illinois. The primary purpose of this amendment is to extend the deadline for receipt of offers from May 13, 2025, to May 15, 2025, at 2:30 PM Central Daylight Time. The amendment serves to officially communicate this extension to all potential offerors and emphasizes that all other terms and conditions of the original solicitation remain unchanged and in full force. The procedural details specified indicate that offers must acknowledge receipt of this amendment in a specified manner prior to the new deadline to be considered valid. This document reflects standard practices within federal procurement processes, ensuring clarity and adherence to regulations while accommodating potential bidders.
    Similar Opportunities
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    NATIONAL OPERATIONAL/MAILING SUPPLIES
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for operational and mailing supplies through solicitation number 36C77025R0004, aimed at supporting its seven Consolidated Mail Outpatient Pharmacy (CMOP) locations. This procurement involves establishing multiple National Single Award Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for essential items such as corrugated boxes, bubble mailers, sealing tape, and child-resistant medical pouches, ensuring compliance with stringent specifications for patient safety and product integrity. The awarded contracts will facilitate timely deliveries of these supplies, which are critical for the efficient processing and shipment of prescriptions to veterans. Interested vendors must submit their proposals, including product samples and pricing schedules in Excel format, by the extended deadline of January 15, 2026, at 5:00 PM CDT. For further inquiries, contact Kelly L Mann at kelly.mann@va.gov or Kelley Cunningham at kelley.cunningham@va.gov.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    6505--LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB (VA-26-00008212)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to supply LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB, as part of solicitation number 36C77026Q0005. This procurement involves delivering a total of 1,460 boxes of the pharmaceutical product to the VA CMOP facility in Hines, Illinois, with a base period and four option years, each requiring delivery by January 5th of the respective year. The goods are critical for patient care within the VA healthcare system, emphasizing the importance of timely and compliant delivery. Interested vendors must submit their proposals, including a signed SF 1449, pricing schedule, and other required documentation, by December 16, 2025, at 3 PM Central Time, and can direct inquiries to Contract Specialist Jennifer Coleman at Jennifer.Coleman4@va.gov.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.